Outcomes After Definitive Surgery for Spinal and Sacral Chordoma in 101 Patients Over 20 Years.
Yuanxuan XiaPritika PapaliAbdel-Hameed Al-MistarehiLandon J HansenTej D AzadA Karim AhmedChristian MeyerJohn GrossMajid KhanChetan BettegowdaDebraj MukherjeeTimothy WithamAli BydonNicholas TheodoreJean-Paul WolinskyZiya GokaslanSheng-Fu Larry LoDaniel SciubbaSang H LeeKristin J RedmondDaniel LubelskiPublished in: Neurosurgery (2024)
Surgeons must often weigh the pros and cons of en bloc resection and sacrificing important but affected native tissues. Our findings can provide a benchmark for counseling patients with spinal chordoma. Tumors ≥100 cm3 appear to have a 5.89-times higher risk of recurrence, mobile spine chordomas have a 7.73 times higher risk, and neoadjuvant radiotherapy confers an 11.1 times lower risk for local recurrence. Patients age ≥65 years at surgery have a 16.70 times higher risk of mortality than those <65 years.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- spinal cord
- peritoneal dialysis
- locally advanced
- cardiovascular disease
- squamous cell carcinoma
- lymph node
- rectal cancer
- type diabetes
- coronary artery disease
- cardiovascular events
- quality improvement
- risk factors
- patient reported outcomes
- acute coronary syndrome
- hepatitis c virus
- smoking cessation
- human immunodeficiency virus